The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Serge Gauthier

McGill Center for studies in Aging

McGill University

Montreal

Canada

[email]@mcgill.ca

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • McGill Center for studies in Aging, McGill University, Montreal, Canada. 2002 - 2012
  • McGill Center for Studies in Aging, Douglas Mental Health University Institute, Douglas Hospital, Verdun, Canada. 2008 - 2010
  • MCSA Alzheimer's Disease Research Unit, McGill Centre for Studies in Aging, Quebec, Canada. 2002 - 2010
  • Department of Psychiatry, Neurology & Neurosurgery, McGill Center for Studies in Aging, McGill University, Canada. 2009
  • Department of Neurology and Neurosurgery, McGill University and Alzheimer Disease Research Unit, McGill Centre for Studies in Aging, Montréal, Canada. 2005

References

  1. Prevention strategies for Alzheimer's disease. Gauthier, S., Wu, L., Rosa-Neto, P., Jia, J. Transl. Neurodegener (2012) [Pubmed]
  2. Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE). Gauthier, S., Juby, A., Dalziel, W., Réhel, B., Schecter, R. Curr. Med. Res. Opin (2010) [Pubmed]
  3. Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease. Gauthier, S., Lopez, O.L., Waldemar, G., Jones, R.W., Cummings, J., Zhang, R., Schindler, R., Schwam, E. Int. Psychogeriatr (2010) [Pubmed]
  4. Management of behavioral problems in Alzheimer's disease. Gauthier, S., Cummings, J., Ballard, C., Brodaty, H., Grossberg, G., Robert, P., Lyketsos, C. Int. Psychogeriatr (2010) [Pubmed]
  5. Can we do better in developing new drugs for Alzheimer's disease? Gauthier, S., Scheltens, P. Alzheimers. Dement (2009) [Pubmed]
  6. Pharmacotherapy of Parkinson disease dementia and Lewy body dementia. Gauthier, S. Frontiers. Neurology. Neuroscience (2009) [Pubmed]
  7. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Gauthier, S., Loft, H., Cummings, J. Int. J. Geriatr. Psychiatry (2008) [Pubmed]
  8. Current and future management of Alzheimer's disease. Gauthier, S., Poirier, J. Alzheimer's & Dementia : J. Alzheimer's Association (2008) [Pubmed]
  9. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease. Gauthier, S., Juby, A., Rehel, B., Schecter, R. Int. J. Clin. Pract. (2007) [Pubmed]
  10. Mild cognitive impairment. Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R.C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., Cummings, J.L., de Leon, M., Feldman, H., Ganguli, M., Hampel, H., Scheltens, P., Tierney, M.C., Whitehouse, P., Winblad, B. Lancet (2006) [Pubmed]
  11. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Gauthier, S., Juby, A., Morelli, L., Rehel, B., Schecter, R. Curr. Med. Res. Opin (2006) [Pubmed]
  12. Aggressive course of disease in dementia. Gauthier, S., Vellas, B., Farlow, M., Burn, D. Alzheimer's & Dementia : J. Alzheimer's Association (2006) [Pubmed]
  13. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Gauthier, S., Wirth, Y., Möbius, H.J. Int. J. Geriatr. Psychiatry (2005) [Pubmed]
  14. Mild cognitive impairment is not a clinical entity and should not be treated. Gauthier, S., Touchon, J. Arch. Neurol. (2005) [Pubmed]
  15. Realizing early treatment benefits in dementia. Gauthier, S.G. Eur. J. Neurol. (2005) [Pubmed]
  16. Alzheimer's disease: the benefits of early treatment. Gauthier, S.G. Eur. J. Neurol. (2005) [Pubmed]
  17. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Gauthier, S., Emre, M., Farlow, M.R., Bullock, R., Grossberg, G.T., Potkin, S.G. Curr. Med. Res. Opin (2003) [Pubmed]
  18. Does vascular MCI progress at a different rate than does amnestic MCI?. Gauthier, S., Rockwood, K. Int. Psychogeriatr (2003) [Pubmed]
  19. Advances in the pharmacotherapy of Alzheimer's disease. Gauthier, S. CMAJ (2002) [Pubmed]
  20. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Gauthier, S., Feldman, H., Hecker, J., Vellas, B., Emir, B., Subbiah, P. Curr. Med. Res. Opin (2002) [Pubmed]
  21. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Gauthier, S., Feldman, H., Hecker, J., Vellas, B., Ames, D., Subbiah, P., Whalen, E., Emir, B. Int. Psychogeriatr (2002) [Pubmed]
  22. Current and future therapeutic strategies for Alzheimer's disease and related dementias. Gauthier, S. Expert. Rev. Neurother (2002) [Pubmed]
 
WikiGenes - Universities